Agoracom Blog Home

Posts Tagged ‘Pharmaceutical’

Empower Clinics Emerges from Stealth Mode: A Game-Changer in Healthcare Innovation

Posted by Paul Nanuwa at 3:49 PM on Monday, April 8th, 2024

Small Cap Clinical Trial Company Sets Stage for Significant Growth

Empower Clinics, a burgeoning force in the healthcare sector, has stepped out of regulatory-mandated stealth mode with a robust growth trajectory and an ambitious plan to restore shareholder value. Led by CEO Steven McAuley, the company is poised for substantial expansion in its research and clinical trials division, marking a pivotal moment in its journey towards industry prominence.

Unveiling the Vision

Empower Clinics is not just another player in the healthcare landscape; it’s a company with a grand vision and a strategic roadmap to revolutionize clinical trials. As it emerges from stealth mode, Empower brings to the forefront a compelling narrative of growth and innovation. With a focus on research and clinical trials, the company has swiftly garnered attention for its early successes in key markets such as Dallas and Los Angeles including already being awarded its first clinical trial from a Global Fortune 500 Pharmaceutical Company.

Foundational Growth and Promising Prospects

Under McAuley’s leadership, Empower has made significant strides in expanding its operational footprint. From just two active sites in the fall, the company has scaled up to six active sites today. Moreover, the number of Principal Investigators has more than doubled, from six to fourteen. This exponential growth not only underscores Empower’s commitment to excellence but also sets the stage for potential contract wins from global pharmaceutical giants.

Seizing Opportunities in a Booming Market

Empower Clinics’ timing couldn’t be more opportune. With the global Clinical Trials Market projected to reach USD 92.45 billion by 2030, fueled by the burgeoning pharmaceutical, biotechnology, and medical device sectors, Empower is primed to capitalize on this burgeoning market. As demographics shift and medical research advances, the company stands at the forefront of innovation, poised to play a pivotal role in shaping the future of healthcare.

Insightful Interview: A Glimpse into Empower’s Strategy

In a compelling interview with AGORACOM, CEO Steven McAuley provided invaluable insights into Empower’s growth trajectory and strategic imperatives. From navigating regulatory challenges to positioning the company for sustainable growth, McAuley’s vision and leadership shine through, offering shareholders and investors a glimpse into the company’s promising future.

Empower Clinics: A Signal of Hope in Healthcare Innovation

As Empower Clinics emerges from stealth mode, it ushers in a new era of innovation and growth in the healthcare sector. With a steadfast commitment to excellence, a robust foundation of operational success, and a visionary leadership team at the helm, the company is well-positioned to unlock tremendous value for shareholders and stakeholders alike.

Conclusion: Charting a Path to Success

Empower Clinics’ journey from stealth mode to growth mode signifies a significant milestone in its evolution as a player in the healthcare industry. With a compelling business model, a strategic focus on research and clinical trials, and a deep commitment to driving shareholder value, Empower is poised to redefine the future of healthcare innovation. As investors and stakeholders alike rally behind the company’s vision, the future looks brighter than ever for Empower Clinics and its pioneering approach to healthcare transformation.


Visit $EPW 5 Minute Research Profile On AGORACOM:
Visit $EPW Official Verified Discussion Forum On AGORACOM:


This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”) is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on, its related websites (;; and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit

VIDEO – Empower Clinics Comes Out Of Stealth Mode With Big Growth And A Grand Plan To Restore Shareholder Value

Posted by Paul Nanuwa at 6:46 PM on Friday, April 5th, 2024

Empower Clinics is a healthcare company with a growing research and clinical trials division that is currently achieving early success in the Dallas and Los Angeles markets, including already being awarded its first clinical trial from a Global Fortune 500 Pharmaceutical Company.

But Empower is just getting started according to CEO Steven McAuley, who has come out of regulator mandated stealth mode to report very promising business growth to shareholders.

Specifically, while under cease trade, Empower has grown their active sites from 2 in the fall to 6 today – and Principal Investigators from 6 to 14 today.  That foundation of doctors and medical offices opens the door to potential major contract wins from pharmaceutical companies that need speed and smarts from partners like Empower to get their clinical trials completed.

Empower’s timing couldn’t be better because Fortune Business Insights states the global Clinical Trials Market size is projected to reach USD 92.45 billion in 2030, driven by expanding pharmaceutical, biotechnology, and medical device R&D pipelines as developed G20 nations demographics get increasingly older.  This positions Empower to play a pivotal role  in this transformative era of healthcare.

Watch this powerful interview with CEO Steven McAuley and AGORACOM Founder George Tsiolis.